HER2 Radioimmunotherapy: Complete Response in Breast Cancer Model
- * Key Finding: HER2-directed therapy using Actinium-225 (225Ac) shows promise as a new treatment for HER2-positive breast cancer and other solid tumors that express HER2.
- In essence, this is a press release or news item about a potentially notable advancement in cancer treatment, specifically targeting HER2-positive cancers.
Here’s a breakdown of the details provided:
* Key Finding: HER2-directed therapy using Actinium-225 (225Ac) shows promise as a new treatment for HER2-positive breast cancer and other solid tumors that express HER2.
* Research Publication: The research is detailed in an article titled “225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast Cancer” published in the Journal of Nuclear Medicine (2025).
* DOI: 10.2967/jnumed.125.269601 (This is a unique identifier for the article, allowing you to find it online).
* Source: The information was provided by the Society of Nuclear Medicine and Molecular Imaging.
* Date: The information was released/retrieved on November 8, 2025.
* Citation: HER2-targeted radioimmunotherapy regimen achieves complete and durable response in breast cancer model (2025, November 8) retrieved 8 November 2025.
In essence, this is a press release or news item about a potentially notable advancement in cancer treatment, specifically targeting HER2-positive cancers.